The EU Court of Justice Advocate General Kokott proposes to uphold the fine of almost €94 million imposed on a pharmaceutical group in the context of agreements intended to delay the marketing of generic versions of its antidepressant medicinal product citalopram (Lundbeck)

Advocate General Kokott proposes that the Court of Justice should uphold the fine of almost €94 million imposed on the Lundbeck pharmaceutical group in the context of agreements intended to delay the marketing of generic versions of its antidepressant medicinal product citalopram* The Advocate General proposes dismissing the appeal brought by Lundbeck against the judgment of the General Court upholding the Commission’s decision imposing that fine By decision of 19 June 2013, [1] the Commission imposed a fine of almost €94 million on the Danish pharmaceutical group Lundbeck, which had developed an antidepressant medicinal product containing an active ingredient called ‘citalopram’. According to the Commission, in 2002, when the patents protecting that active ingredient within the European